SITE: Brownsville, Texas | AGE: 18 to 49 (Part A) and 50 to 85 (Part B) | DURATION: 11 on site visits, 3 phone visits; total 1 year | REIMBURSEMENT: $2000 USD

A Phase I/II, First in human, Observer Blinded, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVIF-19 SARS-CoV-2 Vaccine with CpG Adjuvant in Healthy Seronegative Adults Aged 18-49 and 50-70